by andrewmm2007 | Dec 21, 2023 | Press Releases
The EIB has signed an €18 million venture debt deal with Belgian biotech company Novadip funding innovation on its therapies for rare bone-related genetic diseases. Novadip will further develop its unique bone tissue regeneration platform to create new solutions...
by andrewmm2007 | Dec 5, 2023 | Press Releases
1st US patient treated with an autologous cell-based product (NVD-003) in a rare pediatric disease Full enrollment of patients on track for year-end completion in allogeneic cell-derived product (NVD-X3) trial in patients with a distal radius fracture following...
by andrewmm2007 | May 20, 2023 | CEO Letter
In 2013, we established Novadip Biosciences to develop a new class of regenerative tissue products that will accelerate healing in patients with limited or no effective treatment options. Over the ensuing 10 years we worked to raise capital to support efforts to...
by andrewmm2007 | May 18, 2023 | Press Releases
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* MONT SAINT-GUIBERT, Belgium – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing...
by andrewmm2007 | Apr 20, 2023 | Past Events
Novadip Biosciences will be in Dublin, Ireland May 14-16, 2023 for BioEquity Europe. CEO Dr. Denis Dufrane will be hosting meetings.
